Pfizer Inc. (NYSE: PFE) will conduct additional tests on Pain Therapeutics Inc.'s (Nasdaq: PTIE) pain treatment Remoxy before deciding whether or not to continue developing the medication. Durect Corp.'s (NYSE: DRRX) Oradur technology was used to formulate Remoxy. Shares of Pfizer lost 32 cents to close at $24.55 while Pain Therapeutics stock plummeted $1.71 to close at $2.96. Durect stock plunged 46 cents to close at $0.91.